Topic · Immunology

Safety

Coverage of safety signals across the therapy areas we follow - surveillance protocols, the operational reality of monitoring, and what real-world data tell us about safety beyond the trials. 1 piece on safety in Immunology, newest first within each collection.

← All topics

FilterAll (9)Immunology (1)Neurology (7)Women's Health (1)

Signals

SignalApr 26, 2026FDA · EMA · peer-reviewed

JAK class label restrictions are reshaping moderate-disease prescribing

FDA boxed warnings and EMA caution have repositioned JAK inhibitors as later-line agents in rheumatoid arthritis, atopic dermatitis, and psoriatic arthritis - reshaping the practical sequencing decision in moderate disease.

TreatmentRegulatorySafetyAccess